Detalhe da pesquisa
1.
Perspectives on the Treatment of Multiple Myeloma.
Oncologist
; 29(3): 200-212, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37995307
2.
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Haematologica
; 109(3): 906-914, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646658
3.
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Cancer
; 129(16): 2491-2498, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282609
4.
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
Br J Haematol
; 200(5): 587-594, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495317
5.
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.
Am J Hematol
; 97(7): 942-950, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358350
6.
The Inflation in Oncology Publications and Journals: A Vicious Cycle That Needs Immediate Attention.
Cancer Invest
; : 1-3, 2023 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36592137
7.
Visa Constraints and Career Choices for Oncologists.
J Natl Compr Canc Netw
; 21(3): 332-334, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898360
8.
The Use of Modified Surrogate End Points in Cancer Clinical Trials.
Cancer Invest
; 40(1): 14-16, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775893
9.
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Am J Hematol
; 97(6): E195-E198, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285981
10.
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Am J Hematol
; 97(12): E451-E453, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36097868
11.
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Am J Hematol
; 97(7): E276-E280, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35472167
12.
Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs.
Ann Intern Med
; 173(4): 320-322, 2020 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32568574
13.
Targeting GPRC5D in multiple myeloma.
Expert Rev Anticancer Ther
; 24(5): 229-238, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607646
14.
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Blood Adv
; 8(3): 703-707, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052037
15.
Use of subjective minimizing language at hematology and oncology conferences: A systematic review.
J Cancer Policy
; 39: 100461, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38061494
16.
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
J Clin Invest
; 134(1)2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37883186
17.
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Bone Marrow Transplant
; 59(2): 196-202, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37938736
18.
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Cancers (Basel)
; 16(6)2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539451
19.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Nat Commun
; 15(1): 615, 2024 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242888
20.
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Blood Cancer J
; 14(1): 35, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443345